CANNABOTECH LTDCC

CANNABOTECH LTD

415.6ILAD
−0.4−0.10%
At close at May 22, 14:24 GMT
ILA
No trades
See on Supercharts

CNTC fundamentals

Key facts

Market capitalization‪7.57 M‬ILS
Basic EPS (TTM)−29.31ILS
Founded2019
CEOElchanan Shaked
About

Cannabotech Ltd. engages in research and development, production, and sale of medical and paramedical products based on medical cannabis and mushrooms extracts. It operates through the following segments: Development and sale of Preventive Medicine Products Based on CBD and Medicinal Mushrooms for the British Market; Development of Integrative Oncology Products Based on Medical Cannabis and Nutritional Supplements Based on Mushrooms; and Development of Botanical Medicines. The company was founded by Elchanan Shaked, Dobroslav Melamed, Yoav Rothler, and Sarel Chen-Tov on January 2, 2019 and is headquartered in Hertsliya, Israel.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪7.57 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios
H1 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪21.00‬
‪42.00‬
‪63.00‬
‪84.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−3,800.0%‬
‪−3,100.0%‬
‪−2,400.0%‬
‪−1,700.0%‬
‪−1,000.0%‬
H1 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−16.50 M‬‬
‪‪−11.00 M‬‬
‪‪−5.50 M‬‬
‪0.00‬
‪‪5.50 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−1.20 M‬‬
‪‪−800.00 K‬‬
‪‪−400.00 K‬‬
‪0.00‬
‪‪400.00 K‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−1.20 M‬‬
‪‪−800.00 K‬‬
‪‪−400.00 K‬‬
‪0.00‬
‪‪400.00 K‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
INVALID DATA
By country
Period: 2024
INVALID DATA

Dividends

Dividend yield, history and sustainability

No dividends
CNTC has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
H1 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−12.00 M‬‬
‪‪−8.00 M‬‬
‪‪−4.00 M‬‬
‪0.00‬
‪‪4.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.60 M‬‬
‪‪3.20 M‬‬
‪‪4.80 M‬‬
‪‪6.40 M‬‬
Assets
Liabilities